Azacitidine - CAS 320-67-2
Catalog number: 320-67-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C8H12N4O5
Molecular Weight:
244.2
COA:
Inquire
Targets:
Nucleoside Antimetabolite/Analog
Description:
Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
NSC 102816
MSDS:
Inquire
1.Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C1, Labopin M2, Robin M3, Finke J4, Chevallier P5, Yakoub-Agha I6, Bourhis JH7, Sengelov H8, Blaise D9, Luft T10, Hallek M11, Kröger N12, Nagler A13, Mohty M14. Haematologica. 2016 Apr 14. pii: haematol.2015.140996. [Epub ahead of print]
Disease relapse is the commonest cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplasia yet treatment options for such patients remain limited. Azacitidine is an important new therapy in high risk myelodysplasia and acute myeloid leukaemia but its role in patients who relapse post allograft has not been defined. We studied the tolerability and activity of Azacitidine in 181 patients who relapsed after an allograft for acute myeloid leukaemia (n=116) or myelodysplasia (n=65). 69 patients received additional donor lymphocyte infusions. 46 of 157 (25%) assessable patients responded to Azacitidine therapy: 24 (15%) achieving a complete remission and 22 (14%) a partial remission. Response rates were higher in patients transplanted in complete remission (p= 0.04) and those transplanted for myelodysplasia (p= 0.023). In patients who achieved a complete remission the 2 year overall survival was 48% versus 12% for the whole population.
2.Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L1,2,3, Burgstaller S4, Stauder R5, Girschikofsky M6, Sill H7, Schlick K8,9,10, Thaler J4, Halter B5, Machherndl-Spandl S6, Zebisch A7, Pichler A11, Pfeilstöcker M12, Autzinger EM13, Lang A14, Geissler K15, Voskova D16, Geissler D17, Sperr WR18, Ho J Hematol Oncol. 2016 Apr 16;9:39. doi: 10.1186/s13045-016-0263-4.
BACKGROUND: The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20-30 and AML30+ was made by regulatory agencies by initially restricting approval of azacitidine to AML20-30. Thus, uncertainty prevails regarding the diagnosis, prognosis and optimal treatment timing and strategy for patients with AML20-30. Here, we aim to provide clarification for patients treated with azacitidine front-line.
3.Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H1, Arnan M1, Sánchez-Ortega I1, Sureda A1, Duarte RF1. Mycoses. 2016 Mar 30. doi: 10.1111/myc.12500. [Epub ahead of print]
The aim of this study is to analyse the risk of invasive fungal infection (IFI) and the need for antifungal prophylaxis in patients with acute myeloid leukaemia and myelodysplastic syndromes (AML/MDS) treated with azacitidine. We retrospectively analysed the incidence of IFI according to EORTC-MSG criteria in 121 consecutive AML/MDS patients receiving 948 azacitidine courses (median 5, range 1-43) between June 2007 and June 2015. Four cases of IFI (two possible, one probable aspergillosis and one proven candidemia) occurred in this series. The incidence rate of proven/probable IFI was 0.21% per treatment cycle and 1.6% per patient treated for the whole series, and 0.73% per treatment cycle and 4.1% per patient treated in those with severe neutropenia. Two patients died from IFI, leading to an IFI-attributable mortality rate of 1.65% per patient and 0.21% per treatment cycle. The numbers needed to treat with prophylaxis to prevent one case of IFI are 238 azacitidine cycles or 30 patients throughout their whole treatment course, and 137 azacitidine cycles or 24 patients among those with severe neutropenia.
4.The role of azacitidine in the treatment of elderly patients with AML-results of a retrospective multicenter study.
Tombak A, Uçar MA, Akdeniz A, Tiftik EN, Gören Şahin D, Akay OM, Yıldırım M, Nevruz O, Kış C, Gürkan E, Solmaz ŞM, Özcan MA, Yıldırım R, Berber İ, Erkurt MA, Fıratlı Tuğlular T, Tarkun P, Yavaşoğlu İ, Doğu MH, Sarı İ, Merter M, Özcan M, Yıldızhan E, Kayna Turk J Haematol. 2016 Apr 18. doi: 10.4274/tjh.2015.0203. [Epub ahead of print]
in English, TurkishAmaç: Bu çalışmada, kemik iliğindeki (Kİ) blast oranı >%30 olan vakaları da içeren akut miyeloid lösemili (AML) yaşlı hastalarda, azasitidin’in (AZA) etkinliğinin ve güvenliğinin araştırılmasını amaçladık. Gereç ve Yöntemler: Bu geriye dönük, çok merkezli çalışmaya, yoğun kemoterapi için uygun olmayan ya da konvansiyonel tedavilere rağmen hastalığı ilerleyen ≥60 yaştaki 130 hasta dahil edildi. Bulgular: Ortanca yaş 73 idi, hastaların %61,5’inde Kİ blast oranı >%30 olarak bulundu. Hastalar, ortanca 4 döngü (1-21 aralığında) AZA almıştı. Başlangıç genel yanıt oranı (tam yanıtı (TY)/eksik düzelmenin olduğu TY/kısmi yanıtı içeren) %36,2 idi. Herhangi bir hematolojik düzelme (HD), tüm hastaların %36,2’sinde tespit edildi. HD tedaviye yanıtsız hastaların %27,1’inde de saptandı. Ortanca genel sağkalım, yanıt verenlerde 18 ay, yanıt vermeyenlerde 12 ay idi (p=0,005). Tedaviye yanıtsız hasta grubunda HD’nin, HD olmayanlara kıyasla genel sağkalımı arttırdığı görüldü (ortanca sağkalım 14 aya kıyasla 10 ay, p=0,068).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Nucleoside Antimetabolite/Analog Products


CAS 210829-30-4 Gemcitabine elaidate

Gemcitabine elaidate
(CAS: 210829-30-4)

Gemcitabine elaidate (also known as CO-101; CP-4126) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucl...

CAS 58-61-7 Adenosine

Adenosine
(CAS: 58-61-7)

Adenosine is a purine nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.

Forodesine hydrochloride
(CAS: 284490-13-7)

Forodesine hydrochloride is the hydrochloride salt of Forodesine. Forodesine, also called as BCX-1777 or Immucillin-H, is an orally bioavailable inhibior of mam...

CAS 4342-03-4 Dacarbazine

Dacarbazine
(CAS: 4342-03-4)

Dacarbazine is an antineoplastic chemotherapy drug used in the treatment of various cancers.Dacarbazine is a member of the class of alkylating agents, which des...

CAS 95058-81-4 Gemcitabine

Gemcitabine
(CAS: 95058-81-4)

Gemcitabine is a nucleoside analog used as chemotherapy.

CAS 320-67-2 Azacitidine

Azacitidine
(CAS: 320-67-2)

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

CAS 59-14-3 Bromodeoxyuridine (BrdU)

Bromodeoxyuridine (BrdU)
(CAS: 59-14-3)

Bromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.

CAS 3094-09-5 Doxifluridine

Doxifluridine
(CAS: 3094-09-5)

CAS 50-44-2 Mercaptopurine

Mercaptopurine
(CAS: 50-44-2)

Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methylt...

CAS 154361-50-9 Capecitabine

Capecitabine
(CAS: 154361-50-9)

Capecitabine inhibits tumor growth and metastatic recurrence after resection of human hepatocellular carcinoma (HCC) in highly metastatic nude mice model

CAS 17902-23-7 Tegafur (FT-207, NSC 148958)

Tegafur (FT-207, NSC 148958)
(CAS: 17902-23-7)

Tegafur (FT-207, NSC 148958) is a substance being used in the treatment of some types of cancer.

CAS 147-94-4 Cytarabine

Cytarabine
(CAS: 147-94-4)

Cytarabine (Cytosine arabinoside, AraC) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

CAS 73-24-5 Adenine

Adenine
(CAS: 73-24-5)

Adenine is a purine derivative and a nucleobase with a variety of roles in biochemistry. It can form ATP, which plays a key role in metabolism of cells.

CAS 121032-29-9 Nelarabine

Nelarabine
(CAS: 121032-29-9)

Nelarabine acts by inhibiting DNA synthesis and inducing apoptosis in susceptible cells. Nelarabine demonstrated significant antineoplastic activity with accept...

CAS 75607-67-9 Fludarabine Phosphate

Fludarabine Phosphate
(CAS: 75607-67-9)

Fludarabine Phosphate is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

CAS 51-21-8 Fluorouracil

Fluorouracil
(CAS: 51-21-8)

Fluorouracil (5-Fluoracil, 5-FU) is an DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS).

CAS 122111-03-9 Gemcitabine Hydrochloride

Gemcitabine Hydrochloride
(CAS: 122111-03-9)

Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells.

CAS 65-86-1 Orotic acid

Orotic acid
(CAS: 65-86-1)

Orotic acid is a heterocyclic compound and an acid. It is manufactured in the body via a mitochondrial enzyme, dihydroorotate dehydrogenase, or a cytoplasmic en...

CAS 65-46-3 Cytidine

Cytidine
(CAS: 65-46-3)

Cytidine is a nucleoside molecule that is formed when cytosine is attached to a ribose ring, cytidine is a component of RNA.

CAS 50-91-9 Floxuridine

Floxuridine
(CAS: 50-91-9)

Floxuridine is an antineoplastic antimetabolite, used in the treatment of colon carcinoma and colorectal cancer that has metastasized to the liver.

Chemical Structure

CAS 320-67-2 Azacitidine

Quick Inquiry

Verification code

Featured Items